New Drugs in Development for the Treatment of Diabetes | Zendy

Terri Levien | Zendy; Danial E. Baker | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

New Drugs in Development for the Treatment of Diabetes

Author(s) -

Terri Levien,

Danial E. Baker

Publication year - 2009

Publication title -

diabetes spectrum

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.716

H-Index - 31

eISSN - 1944-7353

pISSN - 1040-9165

DOI - 10.2337/diaspect.22.2.92

Subject(s) - medicine , dipeptidyl peptidase 4 , type 2 diabetes , diabetes mellitus , pharmacology , glucagon like peptide 1 , insulin , receptor , dipeptidyl peptidase , endocrinology , biochemistry , biology , enzyme

In Brief A variety of new agents are in development for the treatment of type 1 or type 2 diabetes. In addition to new dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 analogs, thiazolidinediones, glinides, and new insulin formulations, there are also unique peroxisome proliferator-activated receptor agonists, selective sodium glucose cotransporter 2 inhibitors, and several other unique agents now in development.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research